Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | lactate dehydrogenase protein | 0.016 | 1 | 1 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.016 | 1 | 1 |
Entamoeba histolytica | malate dehydrogenase, putative | 0.016 | 1 | 0.5 |
Echinococcus granulosus | lactate dehydrogenase a | 0.016 | 1 | 1 |
Echinococcus granulosus | L lactate dehydrogenase B chain | 0.016 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | malate dehydrogenase | 0.016 | 1 | 0.5 |
Toxoplasma gondii | lactate dehydrogenase LDH1 | 0.016 | 1 | 0.5 |
Echinococcus multilocularis | lactate dehydrogenase protein | 0.016 | 1 | 1 |
Plasmodium falciparum | L-lactate dehydrogenase | 0.016 | 1 | 0.5 |
Plasmodium vivax | lactate dehydrogenase | 0.016 | 1 | 0.5 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.016 | 1 | 1 |
Toxoplasma gondii | malate dehydrogenase MDH | 0.016 | 1 | 0.5 |
Schistosoma mansoni | malate dehydrogenase | 0.016 | 1 | 0.5 |
Echinococcus multilocularis | L lactate dehydrogenase B chain | 0.016 | 1 | 1 |
Toxoplasma gondii | lactate dehydrogenase LDH2 | 0.016 | 1 | 0.5 |
Plasmodium vivax | malate dehydrogenase, putative | 0.016 | 1 | 0.5 |
Leishmania major | malate dehydrogenase, putative | 0.016 | 1 | 0.5 |
Plasmodium falciparum | malate dehydrogenase | 0.016 | 1 | 0.5 |
Schistosoma mansoni | L-lactate dehydrogenase | 0.016 | 1 | 0.5 |
Echinococcus granulosus | lactate dehydrogenase a | 0.016 | 1 | 1 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.016 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 52.22 % | Analgesic activity in Mus musculus Swiss albino (mouse) assessed as protection against acetic acid-induced writhing effect at 20 mg/kg, po after 3 hr relative to control | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.